Evidence map›Paper›PMID 41721034›Full record

ReviewDiscover oncology2026

Mechanistic insights and clinical implications of RNA-binding proteins in prostate cancer.

Sepide Javankiani, Masoud Khodarahmi, Foroozan Yarahmadi, Seyedeh Tarlan Mirzohreh, Saman Soltani Moghadam, Pegah Kavousinia, Sadegh Moradi, Nahal Aghajamal Avval, Mandana Baghdadi, Nasibeh Sargazi Moghaddam and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sepide Javankiani *Department of Medical Genentics School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0004-1675-7195
Masoud Khodarahmi *Universal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.
Foroozan YarahmadiUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0003-9266-118X
Seyedeh Tarlan MirzohrehUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-5135-0014
Saman Soltani MoghadamUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0003-3905-6589
Pegah KavousiniaUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0003-6910-8095
Sadegh MoradiUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-7837-0624
Nahal Aghajamal AvvalUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0001-8679-5307
Mandana BaghdadiUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0006-8448-228X
Nasibeh Sargazi MoghaddamUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-8398-0643
Mahyar Khanlari GoodarziUniversal Scientific Education and Research Network (USERN), Affiliated with Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0009-0001-3694-093X
Neda Zamen MilaniTabriz Medical Branch, Islamic Azad University, Tabriz, Iran.ORCID http://orcid.org/0009-0008-7158-5129
Faeze Ahmadi BeniDepartment of Medical Genetics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Faezeahmadi137@yahoo.com.ORCID http://orcid.org/0000-0001-6819-0101
Qumars BehfarDepartment of Medical Genentics School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. q_behfar@yahoo.com.ORCID http://orcid.org/0000-0001-5217-924X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) remains one of the most common cancers and the second leading cause of cancer-related morbidity in men worldwide. RNA-binding proteins (RBPs) have emerged as crucial regulators of gene expression via binding to RNAs and influencing their stability, localization, alternative splicing, and translation. Aberrant expression of RBPs causes various diseases, including cancer. Growing evidence has indicated that RBPs participate in PCa tumorigenesis, progression, and therapeutic resistance. Specifically, RBPs can regulate cancerous behaviors of the cells, including proliferation, apoptosis, migration, invasion, and metastasis. This review aims to provide a comprehensive overview of the biological functions of RBPs, as well as the mechanisms by which they contribute to PCa, highlighting their crucial role in regulating signaling pathways and AR signaling. Furthermore, we discuss the clinical applications of RBPs in PCa as both prognostic and diagnostic biomarkers, as well as their potential as therapeutic targets.

Indexed as

BiomarkerProstate cancerRNA binding proteinsRNA-protein interactionTumorigenesisTumor resistance

Identifiers

PMID41721034
PMCPMC13031696

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.